Skip over navigation
The Hospital
Research
Support Us
Ottawa Hospital Research Institute
Home
Français
Directions & Maps
Contact Us
About Us
Vision and Strategic Directions
Board Chair and CEO Message
Leadership Team
Annual Reports
Facilities
Research Data Management
Equity, Diversity and Inclusion
Wellness
Our Research
Priorities, Programs and Diseases
Researcher Profiles
National Research Networks
Scientific Publications
Research Awards
Technology Transfer
Industry Sponsored Research
Responsible Innovation
For Students & Fellows
News & Events
Newsroom
Seminars & Events
Career Opportunities
For Patients
News & Events
Home
>
News & Events
>
Newsroom
Bookmark or Share
Display Options
Display Options
+
Increase
/
-
Decrease
font size
High contrast version
Printer-friendly version
Newsroom
Seminars & Events
Newsroom
Dr. Doug Gray is investigating how lung cancer develops
June 3, 2008
How does cancer develop in the lungs? Can we find a way to stop it in its tracks?
“In lung cancer, mutations in the cells accumulate over time leading to cancer,” says Dr. Douglas Gray. “That is why we usually see lung cancer in older patients and almost never in children.” Dr. Gray holds the University of Ottawa Joan Sealy Chair in Lung Cancer Research and is a Senior Scientist at the Ottawa Hospital Research Institute.
About 85% of lung cancer is attributable to tobacco use, but even in non-smokers lung cancer is a major cause of cancer death in older adults. Dr. Gray says that progress in treating and preventing the disease depends on understanding how DNA errors (or mutations) build up in the cancer cells and why they are not repaired correctly. Early in his career, Dr. Gray discovered one of the first genes in the human ubiquitin pathway and became interested in ubiquitin’s role in DNA repair. More recently he has studied how manipulating ubiquitin levels affects the formation and growth of cancer cells.
“High levels of ubiquitin appear to encourage a form of DNA repair that is error-prone, and we are interesting in knowing how dependent cancer cells are on ubiquitin,” says Dr. Gray. “If we could target this pathway with treatments, we might be able to stop the cancer’s growth.”
Dr. Gray recently received a grant from the Canadian Cancer Society to investigate a newly-identified group of cells know as BASC or bronchioalveolar stem cells. “These cells are really a blank slate,” says Dr. Gray. “BASC were first described in a paper written only three years ago. These cells are an important new focal point for research, because we think that they are where most lung cancers begin.”
Applying Dr. Gray’s previous work on ubiquitin to these cells might one day lead to a way to stop lung cancer at the very earliest stages.
***
This OHRI Scientist in the Spotlight was adapted from a recent Canadian Cancer Society profile of Dr. Gray.
For more information, see:
Dr. Gray’s Canadian Cancer Society Profile
(includes Q&A)
Dr. Gray's OHRI Scientist Profile
OHRI Cancer Therapeutics Program